Connect with us

Media & Technology

MC Endeavors, Inc. (OTCMKTS: MSMY) Blue Sky Breakout as CBD Lab Pioneer Signs Contract with Dr. CBD & Prepares to Hit Big Box Retail Stores in Southern California

Published

on

MC Endeavors, Inc. (OTCMKTS: MSMY) is moving northbound with power in recent days having surpassed previous highs the stock is now on a blue-sky breakout. MSMY is quickly emerging as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation MSMY is moving steadily northbound with many new investors buying in every day. MSMY is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – and MSMY has much stronger fundamentals then Tesoro ever did.  

MSMY is led by high level executive Steven Mazurek who has a history of success and has been working hard behind the scenes with no dilution in over 2 years. Recently MSMY up listed to “pink current” status on OTC Markets and already has an eye on OTCQB. The Company has been making big moves having just signed a 1yr contract with Dr. CBD the number 1 brand on WeedMaps and has a contract with Susan Komen Cancer Org. and will be in big box retail stores in Southern California and test market is going very well. MSMY wholly owned subsidiary Eclipse Liquids is one of only 34 AEMSA certified and FDA registered clean room laboratories and production facilities for eLiquid private label manufacturing in the world.  

MC Endeavors, Inc. (OTCMKTS: MSMY) and its wholly owned subsidiary Eclipse Liquids is the parent company of CBD Liquid Labs operating out of Aliso Viejo, California. Eclipse Liquids provides clients with turnkey CBD product production services including R&D, component sourcing, custom formulation, brand and labels design, label printing, contract and wholesale, custom private label manufacturing and lab certified 3rd party testing to ensure a full service, one stop shop experience. Eclipse Liquids brings CBD product manufacturing solutions to a breadth of markets, including consumer health and wellness, personal care and cosmetics, pharmaceuticals and nutraceuticals, pets, sports, lifestyle fitness and e-liquid tobacco; helping customers introduce innovative products, reduce their time to market, and enhance their overall competitiveness. 

Eclipse Liquids is one of only 34 AEMSA certified and FDA registered clean room laboratories and production facilities for eLiquid private label manufacturing in the world. Through years of honing its manufacturing processes, developing and innovating new products and building a loyal and dedicated staff, Eclipse has grown to become a leader in the CBD Product manufacturing industry. Specializing in private label premium CBD products serving the needs of small-scale businesses to large multi-national companies. The Company offers a broad range of capabilities, from custom recipe development with full production and manufacturing, to confidential private labeling of your branded CBD products. 

MSMY is led by high level executive Steven Mazurek who has a history of success and has been working hard behind the scenes with no dilution in over 2 years. Recently MSMY up listed to “pink current” status on OTC Markets after filing all required financials to OTC Markets for the Company’s December 31, 2019, and 2020 fiscal years as well as First Quarter Financials ending March 31, 2021. Mr. Mazurek has stated he will take MSMY to fully reporting OTCQB once current has been achieved. He has also been beefing up the management team recently announcing Michele King as the Director of Sales. King joins Eclipse Liquids from Enhanced Tech and arrives at a time of rapid expansion. The Company is currently hiring with positions open for a Sales manager, print equipment operator and manufacturing, mixing and product assistant available.  

MSMY acquired Eclipse last year; CEO Steven Mazurek said at the time: “We are very pleased with the results for the first three quarters of the year and we are on track to meet our projections of $1.8 – $2.0 million in revenues for the fiscal year 2019. Since we started selling CBD products in Jan of 2019, this product line is now the fastest growing segment of our business with Q3 over Q2 revenue growth of 32% and Q4 over Q3 growth projected at over 60%. With the new equipment we have already ordered, and the planned product expansion, we expect next year to continue to show significant Q over Q Revenue Growth. We are profitable and reinvesting our profits into additional equipment to meet the growing demands and requests of our clients.”

https://twitter.com/BluntBuyer/status/1424025436418461700

To Find out the inside Scoop on MSMY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

MSMY

On August 5 MSMY announced a huge win for longtime client, Dr. CBD, who recently signed a one-year contract as the exclusive CBD brand for the largest breast cancer organization in the United States, the Susan G. Komen Foundation. 

Rudy Padrol, CEO of Dr. CBD, started in 2018 and through the hard work of Mr. Padrol and the Eclipse team, his ideas became reality. Shortly thereafter, Dr. CBD collaborated with and became the first CBD brand on Weedmaps. With the new exclusive Komen contract, Dr. CBD products are now being testing in Walgreens, Albertsons, Pavilions & Costcos across Southern California. While the data is still coming in from the test locations, Eclipse Liquids is very optimistic with the unlimited potential of the Dr. CBD brand. 

“Dr. CBD is a story about hope,” says Rudy Padrol, from Dr. CBD. “Our goal is doing CBD the ‘right’ way.” With Mr. Padrol’s perseverance overcoming addiction and his dedication to helping others, Eclipse is proud to be a part of this journey with Mr. Padrol & his team and we are anticipating amazing growth very soon. 

For more on MSMY Subscribe Right Now!

MSMY is moving northbound with power in recent days having surpassed previous highs the stock is now on a blue-sky breakout. MSMY is quickly emerging as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation MSMY is moving steadily northbound with many new investors buying in every day. MSMY is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – and MSMY has much stronger fundamentals then Tesoro ever did. MSMY is led by high level executive Steven Mazurek who has a history of success and has been working hard behind the scenes with no dilution in over 2 years. Recently MSMY up listed to “pink current” status on OTC Markets and already has an eye on OTCQB. The Company has been making big moves having just signed a 1yr contract with Dr. CBD the number 1 brand on WeedMaps and has a contract with Susan Komen Cancer Org. and will be in big box retail stores in Southern California and test market is going very well. MSMY wholly owned subsidiary Eclipse Liquids is one of only 34 AEMSA certified and FDA registered clean room laboratories and production facilities for eLiquid private label manufacturing in the world. We will be updating on MSMY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MSMY.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in MSMY either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.